JST [JINPAN INTERNATIONAL] 6-K: (Original Filing)
[]
[Changyou.com Limited to Acquire New Premises in Beijing Safe Harbor Statement CHANGYOU.COM LIMITED Alex Ho, Chief Financial Officer 6-K 1 d6k.htm FORM 6-K]
[Loan Contract Bank of Communication Loan Contract Borrower: Fuwei Films (Shandong) Co., Ltd. Legal Representative: Xiaoan He Legal Address: Hi-Tech Development Zone, Dong Ming Road, Correspondence Address: Same as above Lender: Weifang Branch, Bank of Communication Responsible Person: Lei Wang Correspondence Address: 358 Dong Fang, Dong Street, Weifang Both parties agree to the following terms 1 Loan 1.1 Currency: Renminbi] [Loan Contract Bank of Communication Loan Contract Borrower: Fuwei Films (Shandong) Co., Ltd. Legal Representative: Xiaoan He Legal Address: Hi-Tech Development Zone, Dong Ming Road, Correspondence Address: Same as above Lender: Weifang Branch, Bank of Communication Responsible Person: Lei Wang Correspondence Address: 358 Dong Fang, Dong Street, Weifang Both parties agree to the following terms 12 Loan 12.1 Currency: Renminbi] [Fuwei Films Announces Unaudited Financial Results for Second Quarter of 2009 Teleconference to be Held On Monday, August 17, 2009 At 8:00 A.M. EDT BEIJING, Aug. 14, 2009 (GLOBE NEWSWIRE) -- Fuwei Films (Holdings) Co. Ltd. (Nasdaq:FFHL) ("Fuwei" or the "Company"), a manufacturer and distributor of high-quality BOPET plastic films in China, today announced the unaudited financial results for the] [No. 387 Dongming Road Weifang Shandong People’s Republic of China, Postal Code: 261061 x ¨ Form 20-F ¨ ¨ ¨ ¨ Yes 82-________ EXPLANATORY NOTE On August 14, 2009, the Company announced its unaudited consolidated financial results for the six months period ended June 30, 2009. 2 CONDENSED CONSOLIDATED BALANCE SHEETS AS OF JUNE 30, 2009 AND DECEMBER 31, 2008]
[Changyou.com Limited to Acquire New Premises in Beijingfe Harbor Statement CHANGYOU.COM LIMITEDex Ho, Chief Financial Officer FORM 6-K d6k.htm 1 6-K]
[FORM 10-Q þ For the quarterly period ended June 30, 2009 or o For the transition period from Skystar Bio-Pharmaceutical Company (Exact name of small business issuer as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 33-0901534 (I.R.S. employer identification number) Room 10601, Jiezuo Plaza, No.4, Fenghui Road South, Gaoxin District, Xian Province, P.R. China] [CERTIFICATION I, Weibing Lu, certify that: 1. I have reviewed this Quarterly 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION I, Bennet T. Tchaikovsky, certify that: 1. I have reviewed this Quarterly 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Weibing Lu Weibing Lu Chief Executive Officer EX-32.1 5 v156959_ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Bennet P. Tchaikovsky Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 6 v156959_ex32-2.htm]
[Skystar Bio-Pharmaceutical Announces Second Quarter 2009 Results XI'AN, CHINA – August 14, 2009 – Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) SECOND QUARTER 2009 & RECENT HIGHLIGHTS § Revenues increased 39.4% year-over-year to $6.2 million § Gross margin improved to 52.6% from 51.6% in the second quarter of 2008 § Income from operations increased by 37.6% year-over-year to $1.7 million § Began]
[] [English Summary of Sale and Purchase Agreement dated as of August 5, 2009 I. Summary of the Material Terms of Factory Building Assignment Agreement Date of the Agreement: August 5, 2009 Parties Party A Assignor: Jetcrown Industrial (Shenzhen) Co., Ltd. ( Name of Assignee omitted from this Summary Party B Parties Street address of Assignee omitted from this Summary telephone] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER REQUIRED BY RULE 13A-14(A) I, FRANKI S. F. TSE, certify that: 1. I have reviewed this annual report on Form 20-F of Deswell Industries, Inc. 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [CERTIFICATION OF CHIEF FINANCIAL OFFICER REQUIRED BY RULE 13A-14(A) I, BETTY LAM, certify that: 1. I have reviewed this annual report on Form 20-F of Deswell Industries, Inc. 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Franki S. F. Tse, Chief Executive Officer Betty Lam Chief Financial Officer EX-13.1 5 v53474exv13w1.htm EX-13.1] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Deswell Industries, Inc. We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (File Nos. 333-110236, 333-130738 and 333-147790) of Deswell Industries, Inc. (the Company) of our reports dated August 14, 2009, relating to the consolidated financial statements and the effectiveness of the Companys internal control over financial]
[FORM 10-Q For the quarterly period ended June 30, 2009 or o For the transition period fromystar Bio-Pharmaceuticalmpany (Exact name of small business issuerecified in its charter) Nevada (State or other jurisdiction oforporation or organization) 33-0901534 (I.R.S. employer identification number) Room 10601, Jiezuo Plaza, No.4, Fenghui Road South,] [CERTIFICATION I, Weibing Lu, certify that: 1. I have reviewed this Quarterly 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with] [CERTIFICATION I, Bennet T. Tchaikovsky, certify that: 1. I have reviewed this Quarterly 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Weibing Lu Weibing Lu Chief Executive Officer v156959_ex32-1.htm 5 EX-32.1] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Bennet P. Tchaikovsky Chief Financial Officer (Principal Financial and Accounting Officer) v156959_ex32-2.htm 6 EX-32.2]
[Hurray! Reports Second Quarter 2009 Unaudited Financial Results HRAY News BEIJING, August 12, 2009 /Xinhua-PRNewswire/ Hurray! Holding Co., Ltd. (Nasdaq: Financial Highlights Highlights for the Second Quarter of 2009: Total revenues: $9.8 million, representing a decrease of 16.3% quarter-over-quarter and a decrease of 22.9% year-over-year. Wireless value-added services (WVAS) revenues: $5.5 million, representing a decrease of 29.1%]
[Skystar Bio-Pharmaceutical Announces Second Quarter 2009 Results XI'AN, CHINA August 14, 2009ystar Bio-Pharmaceuticalmpany (NASDAQ:BI) SECOND QUARTER 2009 & RECENT HIGHLIGHTS Revenuesreased 39.4% year-over-year to $6.2 million Gross margin improved to 52.6% from 51.6% in the second quarter of 2008ome from operationsreased by 37.6% year-over-year to $1.7 million]